Compare Moderna, Inc. (MRNA) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Quantum Computing Inc — how do they compare? Moderna, Inc. trades at $224.99 (market cap $78.65B), while Quantum Computing Inc trades at $7.47 (market cap $1.69B). The key difference: Moderna, Inc. is far larger — about 46.5× Quantum Computing Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Quantum Computing Inc for 25 Days on average.
| MRNA | QUBT | |
|---|---|---|
Market Cap | $78.65B | $1.69B |
Volume | 37,373,437 | 7,991,522 |
Sector | Health | Technology |
52-Week High | $203.46 | $21.78 |
52-Week Low | $22.36 | $6.31 |
Typical Hold Time | 59 Days | 25 Days |
Enterprise Value | $74.80B | $753.24M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Quantum Computing Inc. (QUBT) trades at $7.43, down 2.49% today, with a bearish technical signal despite bullish oscillators. The company shows explosive revenue growth from $682K in 2025 to $10M projected for 2026, but remains deeply unprofitable with a -152.45% net income margin. Recent developments include the Dirac-3S quantum system launch and a $42.5M backlog, though rising expenses and shareholder litigation create headwinds.
QUBT offers speculative growth potential in quantum computing with strong analyst support (75% buy rating, $17.33 target) but faces significant execution risks. The stock's appeal hinges on commercializing quantum technology amid persistent losses and competitive threats, requiring careful risk assessment by growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
